University of Texas Texas AM Investment Management Co. Acquires 17,859 Shares of Lantheus Holdings, Inc. $LNTH

University of Texas Texas AM Investment Management Co. increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1,508.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,043 shares of the medical equipment provider’s stock after buying an additional 17,859 shares during the quarter. University of Texas Texas AM Investment Management Co.’s holdings in Lantheus were worth $1,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new position in shares of Lantheus in the second quarter valued at about $575,628,000. Reinhart Partners LLC. lifted its holdings in shares of Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after purchasing an additional 34,501 shares during the period. Carmignac Gestion boosted its position in Lantheus by 0.9% in the second quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock valued at $148,671,000 after buying an additional 12,100 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after buying an additional 582,661 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its position in Lantheus by 59.4% in the first quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock valued at $49,284,000 after buying an additional 242,222 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of Lantheus stock opened at $100.61 on Monday. The stock has a market capitalization of $6.57 billion, a P/E ratio of 24.78 and a beta of 0.01. The business has a 50 day simple moving average of $100.27 and a two-hundred day simple moving average of $92.06. Lantheus Holdings, Inc. has a 12 month low of $50.15 and a 12 month high of $111.86. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.25 and a quick ratio of 3.06.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.45. The business had revenue of $389.91 million during the quarter, compared to analyst estimates of $355.74 million. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The business’s revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.27 earnings per share. As a group, analysts predict that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. TD Cowen lowered Lantheus from a “buy” rating to a “hold” rating and reduced their price objective for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Truist Financial cut Lantheus from a “buy” rating to a “hold” rating and decreased their price objective for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Leerink Partners set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. Brookline Capital Markets downgraded Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings lowered Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 15th. Three analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $107.44.

Lantheus Profile

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology.

The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.